Janssen to collaborate with Jubilant on neuroscience targets
pharmafile | June 29, 2011 | News story | Manufacturing and Production, Research and Development |Â Â Janssen, Jubilant, neuroscience researchÂ
Janssen is to team up with Indian pharma services company Jubilant Life Sciences on neuroscience drug discovery.
Jubilant Discovery Services is an arm of the Indian pharma company which provides a range of services in R&D and manufacturing.
Based in New Jersey in the US, Jubilant Discovery Services offering drug discovery services to pharma, and focuses on target validation and screening solutions.
The alliance with J&J’s pharma division Janssen will aim to deliver pre-clinical candidates over an initial period of three years, and will focus on multiple targets in the area of neuroscience.
Janssen will transfer ongoing projects on selected drug discovery targets to Jubilant. Jubilant will carry out the research services and deliver pre-clinical candidates to Janssen for possible further development and commercialisation. In addition to receiving research funding, Jubilant could also be eligible to receive milestones and royalties should Janssen successfully develop and commercialise the candidates.
Sri Mosur, chief executive and president, Global Drug Discovery and Development, Jubilant, said: “We are very pleased to collaborate with Janssen, a world leader in pharmaceutical research and commercialisation.
“The collaboration will utilise Jubilant’s global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry.”
Staffed with personnel with screening expertise, it will focus in areas of Ion channels, EPHys and screening platforms in GPCR’s and Kinases.
Jubilant Life Sciences is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution (DDDS) provider from India. The Company provides life sciences products and services across the value chain. With 10 world-class manufacturing facilities and has around 5700 employees around the world.
Andrew McConaghie
Related Content
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …
